Policy Analysis Inc, Boston, Massachusetts.
Pfizer Inc, Collegeville, Pennsylvania.
J Infect Dis. 2024 Aug 16;230(2):480-484. doi: 10.1093/infdis/jiad598.
A study of 2 health care claims databases (commercial, Medicaid) was undertaken to estimate the episodic cost of lower respiratory tract illness due to respiratory syncytial virus among infants aged <12 months overall, by age, and by birth gestational age. Among commercial-insured infants, mean costs were $28 812 for hospitalized episodes, $2575 for emergency department episodes, and $336 for outpatient clinic episodes. Costs were highest among infants aged <1 month and infants with a gestational age ≤32 weeks and were comparable among Medicaid-insured infants, albeit somewhat lower. The cost of lower respiratory tract illness due to respiratory syncytial virus during the acute phase of illness is high, especially among the youngest infants and those born premature.
开展了两项医疗保健索赔数据库(商业性保险、医疗补助)研究,旨在估算所有年龄<12 个月、按年龄和胎龄分组的婴儿因呼吸道合胞病毒导致下呼吸道疾病的发作性成本。在商业性保险婴儿中,住院发作的平均费用为 28812 美元,急诊发作的费用为 2575 美元,门诊发作的费用为 336 美元。<1 个月大的婴儿和胎龄≤32 周的婴儿的费用最高,而医疗补助保险婴儿的费用则相当,但略低。呼吸道合胞病毒引起的下呼吸道疾病在疾病急性发作期间的成本很高,尤其是在最小的婴儿和早产儿中。